Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BLOOMFIELD, Conn. , Feb. 9, 2023 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE:CI) announced today that Brian Evanko, executive vice president and chief financial officer, will present at the 43rd  Annual Cowen Health Care Conference on March 6, 2023 in Boston, MA.

Cigna Corporation Announces Appearance at the 43rd Annual Cowen Health Care Conference

Chindata Group Holdings

SUNNYVALE, Calif.--( BUSINESS WIRE )--Cequence Security, the leading provider of Unified API Protection, today announced it has enhanced the testing capabilities within its Unified API Protection Platform with the availability of API Security Testing. This API Security Testing framework encourages shift-left efforts by giving security and development teams the tools to quickly uncover and remediate API vulnerabilities in pre-production environments that could otherwise lead to business disruption in production. To learn more about the new testing capabilities, request a demo here.

Cequence Security Enhances API Security Testing Capabilities

Archer-Daniels-Midland Company

Automatic Data Processing

Applied Materials

Broadcom

BHP Billiton

Blackrock Inc

Costco

Carlisle Companies

Coterra Energy

Chevron

Enterprise Products Partners

Johnson & Johnson

Lennar

Lowe's

Altria

MPLX

Merck

Morgan Stanley

Microsoft

NRG Energy

Pioneer Natural Resources

QUALCOMM

Stanley Black & Decker

Target

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms. It's always a good idea to keep your wish list ready by separating the wheat from the chaff.

5 Relatively Safe And Cheap Dividend Stocks To Invest In - February 2023

CME Group

Camden Property

Quest Diagnostics

Gilead Sciences

Intercontinental Exchange

Invitation Homes

Juniper Networks

Old Dominion Freight Line

Valero Energy

Old Dominion Freight Line, which handles freight shipping logistics, said it will raise its quarterly dividend by 33% to 40 cents from 30 cents.

10 Companies That Boosted Their Dividends This Week

Cigna's (CI) fourth-quarter results reflect the strong contribution from the Evernorth segment. Management sanctions a 10% increase in the quarterly dividend.

Cigna (CI) Q4 Earnings Top on U.S. Commercial Unit, Dividend Up

While the top- and bottom-line numbers for Cigna (CI) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cigna (CI) Reports Q4 Earnings: What Key Metrics Have to Say

Cigna Corporation (NYSE:CI ) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ET Company Participants Ralph Giacobbe - Senior Vice President & Head of Investor Relations David Cordani - President & Chief Executive Officer Brian Evanko - Executive Vice President & Chief Financial Officer Conference Call Participants A.J. Rice - Credit Suisse Gary Taylor - Cowen Erin Wright - Morgan Stanley Kevin Fischbeck - BofA Securities Scott Fidel - Stephens Inc. Justin Lake - Wolfe Research Lisa Gill - JPMorgan Joshua Raskin - Nephron Research Steven Valiquette - Barclays Nathan Rich - Goldman Sachs Lance Wilkes - Sanford C.

Cigna Corporation (CI) Q4 2022 Earnings Call Transcript

Cigna (CI) delivered earnings and revenue surprises of 2.48% and 0.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cigna (CI) Tops Q4 Earnings and Revenue Estimates

Shares of Cigna Corp. CI, -3.75% bounced 1.1% in premarket trading Friday, after closing the previous session at a 3 1/2-month low, after the health insurer reported fourth-quarter profit that topped expectations, while revenue came up a bit shy. Net income rose to $1.17 billion, or $3.83 a share, from $1.12 billion, or $3.39 a share, in the year-ago period.

Cigna stock bounces after profit tops expectations, while revenue comes up shy

Total revenues for 2022 were $180.5 billion Shareholders' net income for 2022 was $6.7 billion, or $21.30 per share Adjusted income from operations1 for 2022 was $7.3 billion, or $23.27 per share Adjusted income from operations1,2 is projected to be at least $7.33 billion in 2023, or at least $24.60 per share2 Board of Directors declared a 10% increase in the quarterly dividend rate, to $1.23 per share BLOOMFIELD, Conn. , Feb. 3, 2023 /PRNewswire/ -- Global health services company Cigna Corporation (NYSE: CI) today reported strong 2022 results reflecting growth in both Evernorth and Cigna Healthcare.

Cigna Reports Strong Fourth Quarter and Full Year 2022 Results, Establishes 2023 Guidance and Increases Dividend

Domino's Pizza

Mastercard

MarketAxess Holdings

Rollins

Charles Schwab

Sherwin-Williams

SPDR S&P 500 ETF Trust

SS&C Technologies Hlds

Skyworks Solutions

Tractor Supply

Visa

Vanguard Dividend Appreciation ETF

Zoetis

I present my top 15 high-growth dividend stocks to consider during the month of February. The watchlist posted a gain of 9.44% in January and starts the new year on a positive note.

My Top 15 High-Growth Dividend Stocks For February 2023

Centene

Elevance Health Inc

Humana

Molina Healthcare

UnitedHealth Group

A proposal for lower-than-expected Medicare Advantage rates in 2024 has sent shares of publicly traded health insurers falling.

Health-insurance stocks drop after Medicare Advantage proposes lower rates for 2024

Herc Hlds

Stride

ONEOK

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Stride (LRN), Herc Holdings (HRI), ONEOK (OKE) and Cigna (CI) are strong enough to meet financial obligations.

Add These 4 Stocks With Amazing Interest Coverage Ratio

Regeneron Pharmaceuticals

Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.

Time to Buy Cigna or Regeneron Stock Before Earnings?

Cigna's (CI) fourth-quarter results are likely to reflect increased Evernorth and Cigna Healthcare profits.

Cigna (CI) to Post Q4 Earnings: Here's What You Should Know

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Cigna (CI) Stock?

AbbVie

Abbott Labs

Aflac

Colgate-Palmolive

Clorox

We present the 2022 year-end review of our eight-year-old Passive DGI-Core Portfolio. We consider this portfolio and strategy as the foundation of our overall portfolio. We will provide updates on changes, additional investments, dividends collected, and an overall 2022 performance.

The 4% DGI Core Portfolio: 2022 Year-End Review

News for Cigna Stock (CI)